Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharvaris N.V. (PHVS)
USD35.05
+0.63 (+1.83%)
NL NASDAQ Healthcare Biotechnology
Address
Grafenauweg 8 6300
Leiden, ZH, NL
Leiden, ZH, NL
CEO
Berndt Modig
Website
pharvaris.com
IPO
2021-02-04
CIK 1830487 ISIN NL00150005Y4
Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD35.05
+0.63 (+1.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
346.9K
Beta
-2.33
Float Shares
27.64M
Free Float %
42.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.80% | -1.82% | +7.04% | +16.07% | +30.36% | +10.63% | +91.04% | +279.01% | +43.73% | +5.86% | +5.86% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
35.05
Low
38.00
+8.4%
Consensus
48.00
+36.9%
Median
42.00
+19.8%
High
74.00
+111.1%
DCF (Unlevered)
5.79
-83.5%
DCF (Levered)
5.80
-83.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 9 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
47.00
+34.1%
|
| Last Year | 7 |
46.00
+31.2%
|
| All Time | 12 |
40.50
+15.5%
|
Quality scores
Altman Z-Score
39.55
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-19.8% Q1'26: +28.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,818.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.5% Q1'26: +19.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 11 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 4 EPS Ana. |
Dec 2030 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
1.34M
92.3K – 3.32M
|
41.01M
2.82M – 101.50M
+2,958.1% YoY
|
148.43M
10.21M – 367.39M
+262.0% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-169.40M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-169.82M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-175.70M
est: -149.54M (-17.5%)
|
-166.19M
-196.59M – -118.70M
-11.1% YoY
|
-148.59M
-186.83M – -110.43M
+10.6% YoY
|
-77.86M
-165.27M – -18.04M
+47.6% YoY
|
58.02M
-12.22M – 169.28M
+174.5% YoY
|
222.72M
-46.89M – 649.83M
+283.9% YoY
|
| SGA |
45.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.97
est: -2.74 (-8.4%)
|
-2.81
-3.32 – -2.01
-2.6% YoY
|
-2.52
-3.16 – -1.87
+10.3% YoY
|
-1.15
-2.79 – -0.30
+54.6% YoY
|
0.98
-0.21 – 2.86
+185.6% YoY
|
3.76
-0.79 – 10.98
+283.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
7.70M
Insider transactions (90d)
18
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LSP V Coöperatieve U.A. | 3.61M | 10.90% | — | 3.61M | — | 3.61M | OO | — | 2022-02-03 | ↗ |
| 2 | LSP V Management B.V. | 3.61M | 10.90% | — | 3.61M | — | 3.61M | OO | — | 2022-02-03 | ↗ |
| 3 | James Tananbaum (“Tananbaum”) | 3.30M | 9.90% | 3.30M | 3.30M | 3.30M | — | IN | — | 2022-02-11 | ↗ |
| 4 | Abigail P. Johnson | 3.30M | 9.95% | — | — | 3.30M | — | IN | United States of America | 2022-02-09 | ↗ |
| 5 | FMR LLC | 3.30M | 9.95% | 168.5K | — | 3.30M | — | HC | Delaware | 2022-02-09 | ↗ |
| 6 | Foresite Capital Fund IV, L.P. (“FCF IV”) | 3.26M | 9.80% | 3.26M | 3.26M | 3.26M | — | PN | — | 2022-02-11 | ↗ |
| 7 | Foresite Capital Management IV, LLC (“FCM IV”) | 3.26M | 9.80% | 3.26M | 3.26M | 3.26M | — | OO | — | 2022-02-11 | ↗ |
| 8 | Bain Capital Life Sciences Fund, L.P. | 2.89M | 9.10% | — | 2.89M | — | 2.89M | PN | Cayman Islands | 2021-02-19 | ↗ |
| 9 | Koh, Bong | 2.48M | 6.10% | — | 2.48M | — | — | IN | Delaware | 2023-11-30 | ↗ |
| 10 | Shah, Nimish | 2.48M | 6.10% | — | 2.48M | — | — | IN | Delaware | 2023-11-30 | ↗ |
| 11 | VHCP Co-Investment Holdings III, LLC | 2.48M | 6.10% | — | 2.48M | — | — | OO | Delaware | 2023-11-30 | ↗ |
| 12 | VHCP Management EG, LLC | 2.48M | 6.10% | — | 2.48M | — | — | OO | Delaware | 2023-11-30 | ↗ |
| 13 | VHCP Management III, LLC | 2.48M | 6.10% | — | 2.48M | — | — | OO | Delaware | 2023-11-30 | ↗ |
| 14 | Venrock Healthcare Capital Partners EG, L.P. | 2.48M | 6.10% | — | 2.48M | — | — | PN | Delaware | 2023-11-30 | ↗ |
| 15 | Venrock Healthcare Capital Partners III, L.P. | 2.48M | 6.10% | — | 2.48M | — | — | PN | Delaware | 2023-11-30 | ↗ |
| 16 | Viking Global Investors LP | 2.46M | 7.40% | — | 2.46M | — | 2.46M | PN | Delaware | 2022-02-14 | ↗ |
| 17 | General Atlantic LLC | 2.42M | 7.30% | — | 2.42M | — | 2.42M | OO | Delaware | 2021-02-19 | ↗ |
| 18 | Aaron Royston | 2.30M | 7.00% | — | 2.30M | — | 2.30M | IN | — | 2021-02-19 | ↗ |
| 19 | Corey Goodman | 2.30M | 7.00% | — | 2.30M | — | 2.30M | IN | — | 2021-02-19 | ↗ |
| 20 | Robert Adelman | 2.30M | 7.00% | — | 2.30M | — | 2.30M | IN | — | 2021-02-19 | ↗ |
| 21 | venBio Global Strategic Fund III, L.P. | 2.30M | 7.00% | — | 2.30M | — | 2.30M | PN | — | 2021-02-19 | ↗ |
| 22 | venBio Global Strategic GP III, L.P. | 2.30M | 7.00% | — | 2.30M | — | 2.30M | PN | — | 2021-02-19 | ↗ |
| 23 | BCIP Life Sciences Associates, LP | 295.3K | 0.90% | — | 295.3K | — | 295.3K | PN | Cayman Islands | 2021-02-19 | ↗ |
| 24 | Foresite Capital Fund V, L.P. (“FCF V”) | 34.1K | 0.10% | 34.1K | 34.1K | 34.1K | — | PN | — | 2022-02-11 | ↗ |
| 25 | Foresite Capital Management V, LLC (“FCM V”) | 34.1K | 0.10% | 34.1K | 34.1K | 34.1K | — | OO | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-94 vs prev Q
New positions
0
Closed positions
92
Increased
4
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 198.8K +198.8K (+100.0%) | 5.52B +5.5B (+100.0%) | 0.32% +0.319 pp | 5.46% +5.456 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 2 | GENERAL ATLANTIC, L.P. | 8.03M +— (+0.0%) | 222.87M +22.5M (+11.2%) | 12.90% +0.000 pp | 7.76% +1.742 pp | USD23.55 +17.8% | 20 qtrs — |
| 3 | FMR LLC | 6.40M +— (+0.0%) | 177.58M +17.9M (+11.2%) | 10.28% +0.000 pp | 0.01% +0.001 pp | USD26.29 +5.6% | 20 qtrs — |
| 4 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 5.0K +5.0K (+100.0%) | 138.75M +138.8M (+100.0%) | 0.01% +0.008 pp | 0.12% +0.118 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 5 | FORESITE CAPITAL MANAGEMENT IV, LLC | 4.78M +— (+0.0%) | 132.61M +13.4M (+11.2%) | 7.68% +0.000 pp | 57.73% -7.563 pp | USD25.68 +8.1% | 20 qtrs — |
| 6 | VENBIO PARTNERS LLC | 4.64M +— (+0.0%) | 128.74M +13.0M (+11.2%) | 7.45% +0.000 pp | 59.53% -6.090 pp | USD22.97 +20.8% | 20 qtrs — |
| 7 | VIKING GLOBAL INVESTORS LP | 3.65M +— (+0.0%) | 101.38M +10.2M (+11.2%) | 5.87% +0.000 pp | 0.27% +0.032 pp | USD24.27 +14.3% | 20 qtrs — |
| 8 | EQT FUND MANAGEMENT S.A R.L. | 3.42M +— (+0.0%) | 95.03M +9.6M (+11.2%) | 5.50% +0.000 pp | 8.55% +3.960 pp | USD24.95 +11.2% | 2 qtrs — |
| 9 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3.13M +683.6K (+28.0%) | 86.75M +25.8M (+42.4%) | 5.02% +1.098 pp | 1.11% +0.178 pp | USD24.14 +15.0% | 9 qtrs — |
| 10 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 2.80M -379.2K (-11.9%) | 77.76M -1.6M (-2.0%) | 4.50% -0.609 pp | 5.96% +0.687 pp | USD23.53 +17.9% | 20 qtrs — |
| 11 | WELLINGTON MANAGEMENT GROUP LLP | 1.91M +171.1K (+9.9%) | 52.89M +9.6M (+22.2%) | 3.06% +0.275 pp | 0.01% +0.002 pp | USD25.20 +10.1% | 2 qtrs — |
| 12 | COMMODORE CAPITAL LP | 1.89M -529.0K (-21.9%) | 52.43M -7.9M (-13.1%) | 3.04% -0.850 pp | 3.49% +0.545 pp | USD24.22 +14.6% | 9 qtrs — |
| 13 | NOVO HOLDINGS A/S | 1.75M +— (+0.0%) | 48.56M +4.9M (+11.2%) | 2.81% +0.000 pp | 3.77% +0.957 pp | USD16.58 +67.4% | 20 qtrs — |
| 14 | SATURN V CAPITAL MANAGEMENT LLC | 1.14M +253.7K (+28.6%) | 31.64M +9.5M (+43.1%) | 1.83% +0.408 pp | 5.81% +0.956 pp | USD25.57 +8.5% | 2 qtrs — |
| 15 | CORMORANT ASSET MANAGEMENT, LP | 1.08M -280.2K (-20.6%) | 30.05M -4.0M (-11.6%) | 1.74% -0.450 pp | 1.39% -0.957 pp | USD23.64 +17.4% | 20 qtrs — |
| 16 | PRICE T ROWE ASSOCIATES INC /MD/ | 941.6K +124.8K (+15.3%) | 26.13M +5.8M (+28.2%) | 1.51% +0.201 pp | 0.00% +0.001 pp | USD22.85 +21.4% | 9 qtrs — |
| 17 | 5AM VENTURE MANAGEMENT, LLC | 797.6K +— (+0.0%) | 22.13M +2.2M (+11.2%) | 1.28% +0.000 pp | 6.96% -0.330 pp | USD23.67 +17.2% | 15 qtrs — |
| 18 | SOFINNOVA INVESTMENTS, INC. | 745.2K +5.3K (+0.7%) | 20.68M +2.2M (+12.0%) | 1.20% +0.009 pp | 0.89% -0.118 pp | USD26.09 +6.4% | 9 qtrs — |
| 19 | POINT72 ASSET MANAGEMENT, L.P. | 711.6K +192.2K (+37.0%) | 19.75M +6.8M (+52.4%) | 1.14% +0.309 pp | 0.02% +0.000 pp | USD25.25 +9.9% | 5 qtrs — |
| 20 | BLACKROCK, INC. | 708.6K +294.1K (+71.0%) | 19.66M +9.3M (+90.2%) | 1.14% +0.473 pp | 0.00% +0.000 pp | USD24.28 +14.3% | 6 qtrs — |
| 21 | SOLEUS CAPITAL MANAGEMENT, L.P. | 702.1K +55.0K (+8.5%) | 19.48M +3.3M (+20.7%) | 1.13% +0.088 pp | 0.72% -0.094 pp | USD18.35 +51.2% | 13 qtrs — |
| 22 | OCTAGON CAPITAL ADVISORS LP | 671.5K -51.1K (-7.1%) | 18.63M +604.4K (+3.4%) | 1.08% -0.082 pp | 2.26% -0.470 pp | USD19.09 +45.4% | 6 qtrs — |
| 23 | KYNAM CAPITAL MANAGEMENT, LP | 640.4K -34.6K (-5.1%) | 17.77M +929.7K (+5.5%) | 1.03% -0.056 pp | 1.14% -0.119 pp | USD24.95 +11.2% | 2 qtrs — |
| 24 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 623.4K +— (+0.0%) | 17.30M +1.7M (+11.2%) | 1.00% +0.000 pp | 0.89% -0.022 pp | USD21.57 +28.7% | 8 qtrs — |
| 25 | PATIENT SQUARE CAPITAL LP | 542.7K +197.3K (+57.1%) | 15.06M +6.4M (+74.8%) | 0.87% +0.317 pp | 3.22% +0.919 pp | USD22.88 +21.3% | 6 qtrs — |
| 26 | BALYASNY ASSET MANAGEMENT L.P. | 496.3K -129.5K (-20.7%) | 13.77M -1.8M (-11.8%) | 0.80% -0.208 pp | 0.02% -0.002 pp | USD24.95 +11.2% | 2 qtrs — |
| 27 | IKARIAN CAPITAL, LLC | 486.9K +276.7K (+131.7%) | 13.51M +8.3M (+157.7%) | 0.78% +0.444 pp | 1.05% +0.525 pp | USD26.54 +4.6% | 2 qtrs — |
| 28 | EVERSEPT PARTNERS, LP | 439.2K +439.2K (+100.0%) | 12.19M +12.2M (+100.0%) | 0.71% +0.705 pp | 0.61% +0.614 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 29 | BAKER BROS. ADVISORS LP | 375.0K +— (+0.0%) | 10.41M +1.1M (+11.2%) | 0.60% +0.000 pp | 0.06% -0.007 pp | USD24.95 +11.2% | 2 qtrs — |
| 30 | D. E. SHAW & CO., INC. | 260.6K +237.7K (+1,038.6%) | 7.23M +6.7M (+1,166.3%) | 0.42% +0.382 pp | 0.00% +0.004 pp | USD27.50 +0.9% | 2 qtrs — |
| 31 | MILLENNIUM MANAGEMENT LLC | 248.9K +142.3K (+133.6%) | 6.91M +4.2M (+159.8%) | 0.40% +0.229 pp | 0.00% +0.002 pp | USD26.16 +6.1% | 9 qtrs — |
| 32 | MORGAN STANLEY | 248.3K +190.1K (+326.2%) | 6.89M +5.4M (+374.1%) | 0.40% +0.305 pp | 0.00% +0.000 pp | USD24.94 +11.3% | 20 qtrs — |
| 33 | POLAR CAPITAL HOLDINGS PLC | 238.0K -26.7K (-10.1%) | 6.60M -644.0 (0.0%) | 0.38% -0.043 pp | 0.03% -0.006 pp | USD24.95 +11.2% | 2 qtrs — |
| 34 | TWO SIGMA INVESTMENTS, LP | 215.2K +204.6K (+1,928.7%) | 5.97M +5.7M (+2,156.4%) | 0.35% +0.329 pp | 0.01% +0.008 pp | USD27.61 +0.5% | 2 qtrs — |
| 35 | ORBIMED ADVISORS LLC | 205.4K +205.4K (+100.0%) | 5.70M +5.7M (+100.0%) | 0.33% +0.330 pp | 0.12% +0.117 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 36 | TFG ASSET MANAGEMENT GP LTD | 194.6K +— (+0.0%) | 5.40M +544.9K (+11.2%) | 0.31% +0.000 pp | 1.14% +0.489 pp | USD16.61 +67.1% | 4 qtrs — |
| 37 | HIGHVISTA STRATEGIES LLC | 162.4K +162.4K (+100.0%) | 4.51M +4.5M (+100.0%) | 0.26% +0.261 pp | 1.16% +1.160 pp | USD27.75 +0.0% | 8 qtrs — |
| 38 | STATE STREET CORP | 161.5K +18.7K (+13.1%) | 4.48M +919.4K (+25.8%) | 0.26% +0.030 pp | 0.00% +0.000 pp | USD21.67 +28.1% | 6 qtrs — |
| 39 | GOLDMAN SACHS GROUP INC | 160.9K +146.4K (+1,011.6%) | 4.47M +4.1M (+1,136.3%) | 0.26% +0.235 pp | 0.00% +0.001 pp | USD27.50 +0.9% | 2 qtrs — |
| 40 | BOOTHBAY FUND MANAGEMENT, LLC | 157.1K +21.9K (+16.2%) | 4.36M +987.2K (+29.3%) | 0.25% +0.035 pp | 0.07% +0.016 pp | USD24.58 +12.9% | 3 qtrs — |
| 41 | SCHRODER INVESTMENT MANAGEMENT GROUP | 158.0K +145.9K (+1,208.9%) | 4.15M +3.9M (+1,316.2%) | 0.25% +0.234 pp | 0.00% +0.003 pp | USD27.54 +0.8% | 2 qtrs — |
| 42 | UBS GROUP AG | 137.7K +7.0K (+5.3%) | 3.82M +559.9K (+17.2%) | 0.22% +0.011 pp | 0.00% +0.000 pp | USD24.85 +11.7% | 7 qtrs — |
| 43 | CITADEL ADVISORS LLC | 135.1K +5.3K (+4.1%) | 3.75M +511.2K (+15.8%) | 0.22% +0.009 pp | 0.00% +0.000 pp | USD23.47 +18.2% | 3 qtrs — |
| 44 | ALYESKA INVESTMENT GROUP, L.P. | 125.0K +— (+0.0%) | 3.47M +350.0K (+11.2%) | 0.20% +0.000 pp | 0.01% +0.000 pp | USD24.95 +11.2% | 2 qtrs — |
| 45 | TD ASSET MANAGEMENT INC | 120.2K +15.9K (+15.2%) | 3.34M +733.2K (+28.2%) | 0.19% +0.026 pp | 0.00% +0.001 pp | USD20.34 +36.4% | 8 qtrs — |
| 46 | SQUAREPOINT OPS LLC | 100.4K +100.4K (+100.0%) | 2.78M +2.8M (+100.0%) | 0.16% +0.161 pp | 0.00% +0.003 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 47 | LOGOS GLOBAL MANAGEMENT LP | 100.0K -50.0K (-33.3%) | 2.78M -967.5K (-25.9%) | 0.16% -0.080 pp | 0.17% -0.168 pp | USD24.95 +11.2% | 2 qtrs — |
| 48 | TWO SIGMA ADVISERS, LP | 89.6K +89.6K (+100.0%) | 2.49M +2.5M (+100.0%) | 0.14% +0.144 pp | 0.00% +0.005 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 49 | GEODE CAPITAL MANAGEMENT, LLC | 86.8K +8.3K (+10.5%) | 2.41M +449.1K (+22.9%) | 0.14% +0.013 pp | 0.00% +0.000 pp | USD23.27 +19.3% | 20 qtrs — |
| 50 | ADAR1 CAPITAL MANAGEMENT, LLC | 85.5K +51.4K (+150.6%) | 2.37M +1.5M (+178.8%) | 0.14% +0.083 pp | 0.17% +0.094 pp | USD23.70 +17.1% | 3 qtrs — |
| 51 | TREXQUANT INVESTMENT LP | 84.4K +84.4K (+100.0%) | 2.34M +2.3M (+100.0%) | 0.14% +0.136 pp | 0.02% +0.021 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 52 | UBS ASSET MANAGEMENT AMERICAS INC | 83.9K +83.9K (+100.0%) | 2.33M +2.3M (+100.0%) | 0.13% +0.135 pp | 0.00% +0.001 pp | USD27.75 +0.0% | 6 qtrs — |
| 53 | GREAT POINT PARTNERS LLC | 82.8K -72.3K (-46.6%) | 2.30M -1.6M (-40.6%) | 0.13% -0.116 pp | 0.75% -0.851 pp | USD24.95 +11.2% | 2 qtrs — |
| 54 | NORTHERN TRUST CORP | 81.0K +3.1K (+4.0%) | 2.25M +303.7K (+15.6%) | 0.13% +0.005 pp | 0.00% +0.000 pp | USD19.27 +44.0% | 6 qtrs — |
| 55 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 79.9K +20.1K (+33.6%) | 2.10M +605.4K (+40.6%) | 0.13% +0.032 pp | 0.00% +0.001 pp | USD26.52 +4.6% | 9 qtrs — |
| 56 | SPHERA FUNDS MANAGEMENT LTD. | 64.0K -55.5K (-46.4%) | 1.77M -1.2M (-40.4%) | 0.10% -0.089 pp | 0.34% -0.285 pp | USD24.89 +11.5% | 9 qtrs — |
| 57 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 61.6K +61.6K (+100.0%) | 1.71M +1.7M (+100.0%) | 0.10% +0.099 pp | 0.00% +0.000 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 58 | BNP PARIBAS ARBITRAGE, SNC | 59.0K +58.6K (+14,194.7%) | 1.64M +1.6M (+15,799.4%) | 0.09% +0.094 pp | 0.00% +0.001 pp | USD27.69 +0.2% | 5 qtrs — |
| 59 | STEMPOINT CAPITAL LP | 58.4K +58.4K (+100.0%) | 1.62M +1.6M (+100.0%) | 0.09% +0.094 pp | 0.28% +0.278 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 60 | DEUTSCHE BANK AG\ | 56.4K +4.6K (+8.8%) | 1.56M +272.2K (+21.1%) | 0.09% +0.007 pp | 0.00% +0.000 pp | USD21.49 +29.1% | 6 qtrs — |
| 61 | ALPS ADVISORS INC | 52.6K +52.6K (+100.0%) | 1.46M +1.5M (+100.0%) | 0.08% +0.085 pp | 0.01% +0.009 pp | USD27.75 +0.0% | 6 qtrs — |
| 62 | SWISS NATIONAL BANK | 44.8K +2.4K (+5.7%) | 1.24M +185.2K (+17.5%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD21.33 +30.1% | 6 qtrs — |
| 63 | TUDOR INVESTMENT CORP ET AL | 32.0K -45.9K (-58.9%) | 888.8K -1.1M (-54.3%) | 0.05% -0.091 pp | 0.00% -0.002 pp | USD24.95 +11.2% | 2 qtrs — |
| 64 | MARSHALL WACE, LLP | 31.8K +4.7K (+17.5%) | 883.3K +207.3K (+30.7%) | 0.05% +0.008 pp | 0.00% +0.000 pp | USD25.37 +9.4% | 2 qtrs — |
| 65 | BIRCHVIEW CAPITAL, LP | 29.8K +15.0K (+101.0%) | 828.3K +457.8K (+123.6%) | 0.05% +0.024 pp | 0.48% +0.205 pp | USD26.36 +5.3% | 2 qtrs — |
| 66 | QUADRATURE CAPITAL LTD | 28.9K +28.9K (+100.0%) | 802.5K +802.5K (+100.0%) | 0.05% +0.047 pp | 0.01% +0.008 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 67 | AMUNDI | 27.6K -13.9K (-33.4%) | 767.0K -198.3K (-20.5%) | 0.04% -0.022 pp | 0.00% 0.000 pp | USD20.10 +38.1% | 6 qtrs — |
| 68 | JUMP FINANCIAL, LLC | 26.3K +26.3K (+100.0%) | 729.8K +729.8K (+100.0%) | 0.04% +0.042 pp | 0.01% +0.009 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 69 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 24.0K +520.0 (+2.2%) | 665.5K +80.1K (+13.7%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD21.21 +30.8% | 6 qtrs — |
| 70 | SUMMITTX CAPITAL, L.P. | 22.9K +22.9K (+100.0%) | 634.3K +634.3K (+100.0%) | 0.04% +0.037 pp | 0.02% +0.019 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 71 | LEGAL & GENERAL GROUP PLC | 22.7K +— (+0.0%) | 629.0K +63.5K (+11.2%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD21.63 +28.3% | 6 qtrs — |
| 72 | JPMORGAN CHASE & CO | 21.9K -5.1K (-19.0%) | 608.9K -66.9K (-9.9%) | 0.04% -0.014 pp | 0.00% +0.000 pp | USD24.19 +14.7% | 11 qtrs — |
| 73 | PALUMBO WEALTH MANAGEMENT LLC | 20.2K +3.5K (+21.3%) | 560.1K +144.9K (+34.9%) | 0.03% +0.006 pp | 0.14% +0.006 pp | USD20.57 +34.9% | 5 qtrs — |
| 74 | BANK OF AMERICA CORP /DE/ | 19.6K +901.0 (+4.8%) | 542.7K +77.2K (+16.6%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD20.34 +36.4% | 8 qtrs — |
| 75 | VANGUARD GROUP INC | 19.3K +— (+0.0%) | 535.9K +54.1K (+11.2%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD24.95 +11.2% | 6 qtrs — |
| 76 | XTX TOPCO LTD | 18.6K +10.4K (+126.1%) | 515.3K +310.3K (+151.5%) | 0.03% +0.017 pp | 0.01% +0.003 pp | USD26.51 +4.7% | 2 qtrs — |
| 77 | VERITION FUND MANAGEMENT LLC | 17.9K +17.9K (+100.0%) | 496.7K +496.7K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.002 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 78 | NUVEEN, LLC | 17.0K +— (+0.0%) | 471.9K +47.6K (+11.2%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD24.95 +11.2% | 2 qtrs — |
| 79 | HRT FINANCIAL LP | 14.8K -11.4K (-43.7%) | 409.0K -244.0K (-37.4%) | 0.02% -0.018 pp | 0.00% -0.001 pp | USD24.95 +11.2% | 2 qtrs — |
| 80 | QUBE RESEARCH & TECHNOLOGIES LTD | 14.7K +14.7K (+100.0%) | 408.1K +408.1K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 81 | JANE STREET GROUP, LLC | 12.6K +12.6K (+100.0%) | 349.7K +349.7K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 82 | OCCUDO QUANTITATIVE STRATEGIES LP | 12.3K +12.3K (+100.0%) | 342.7K +342.7K (+100.0%) | 0.02% +0.020 pp | 0.02% +0.023 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 83 | VIRTUS INVESTMENT ADVISERS, INC. | 11.0K +4.4K (+66.7%) | 305.6K +140.8K (+85.4%) | 0.02% +0.007 pp | 0.08% +0.036 pp | USD21.49 +29.1% | 4 qtrs — |
| 84 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 10.4K +7.4K (+247.9%) | 289.7K +214.8K (+287.0%) | 0.02% +0.012 pp | 0.02% +0.016 pp | USD26.95 +3.0% | 2 qtrs — |
| 85 | ALLIANCEBERNSTEIN L.P. | 9.0K +— (+0.0%) | 249.2K +25.1K (+11.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD24.95 +11.2% | 2 qtrs — |
| 86 | TEACHER RETIREMENT SYSTEM OF TEXAS | 8.9K +8.9K (+100.0%) | 247.3K +247.3K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.001 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 87 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 8.2K +2.8K (+50.1%) | 228.6K +91.7K (+66.9%) | 0.01% +0.004 pp | 0.00% +0.001 pp | USD24.22 +14.6% | 5 qtrs — |
| 88 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 7.6K +1.3K (+20.7%) | 210.0K +53.6K (+34.3%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD21.27 +30.5% | 6 qtrs — |
| 89 | KLP KAPITALFORVALTNING AS | 5.8K +— (+0.0%) | 161.0K +16.2K (+11.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD19.17 +44.8% | 5 qtrs — |
| 90 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 5.5K +2.2K (+69.0%) | 153.0K +72.0K (+88.9%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD21.74 +27.6% | 3 qtrs — |
| 91 | QUANTBOT TECHNOLOGIES LP | 4.3K +4.3K (+100.0%) | 118.2K +118.2K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.004 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 92 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 4.0K +4.0K (+100.0%) | 110.4K +110.4K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 93 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 3.1K +3.1K (+100.0%) | 86.4K +86.4K (+100.0%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD27.75 +0.0% | 1 qtrs NEW |
| 94 | BARCLAYS PLC | 2.8K -2.9K (-51.3%) | 77.0K -28.6K (-27.1%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD21.80 +27.3% | 6 qtrs — |
| 95 | CITIGROUP INC | 1.8K +1.2K (+216.8%) | 49.6K +35.5K (+252.4%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD25.05 +10.8% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 31 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.70% | 404.5K | 0.65% |
| 2 | Fidelity Disruptive Medicine ETF FMED | 0.52% | 241.9K | 0.50% |
| 3 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.22% | 1.53M | 0.40% |
| 4 | iShares MSCI Netherlands ETF EWN | 0.21% | 1.10M | 0.50% |
| 5 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.17% | 779.7K | 0.40% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.17% | 1.84M | 0.35% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.17% | 123.4K | 0.35% |
| 8 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.12% | 867.6K | 0.33% |
| 9 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.11% | 1.18M | 0.58% |
| 10 | State Street SPDR S&P International Small Cap ETF GWX | 0.10% | 834.4K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.26
Bearish
Ratio by volume
0.29
Bearish
Buys
10
Sells
39
Shares acquired
69.3K
Shares disposed
241.0K
Cash buys
—
Cash sales
23.00
Net activity
-171,730
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-03 | Schikan Johannes Gerardus Christiaan Petrus | Director | — | — | Stock Option (Right to Buy) | 16,500 | 28.00 | 462.0K | 0 | D | ↗ |
| 2027-03-03 | Monges Viviane | Director | — | — | Stock Option (Right to Buy) | 16,500 | 28.00 | 462.0K | 0 | D | ↗ |
| 2027-03-03 | Meeker David P | Director | — | — | Stock Option (Right to Buy) | 16,500 | 28.00 | 462.0K | 0 | D | ↗ |
| 2027-03-03 | Glassman Robert | Director | — | — | Stock Option (Right to Buy) | 16,500 | 28.00 | 462.0K | 0 | D | ↗ |
| 2027-03-03 | Bjork Elisabeth | Director | — | — | Stock Option (Right to Buy) | 16,500 | 28.00 | 462.0K | 0 | D | ↗ |
| 2026-05-01 | Lu Peng | Officer | M-Exempt | D | Stock Option (Right to Buy) | 14,023 | 2.59 | 36.3K | 205,451 | D | ↗ |
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus | Director | S-Sale | D | Common Stock | 670 | 31.03 | 20.8K | 355,167 | D | ↗ |
| 2026-04-30 | Lu Peng | Officer | S-Sale | D | Common Stock | 15,000 | 30.24 | 453.6K | 66,083 | D | ↗ |
| 2026-04-30 | Lesage Anne | Officer | S-Sale | D | Common Stock | 18,000 | 30.26 | 544.6K | 56,450 | D | ↗ |
| 2026-04-29 | Schikan Johannes Gerardus Christiaan Petrus | Director | S-Sale | D | Common Stock | 3,830 | 30.07 | 115.2K | 384,237 | D | ↗ |
| 2026-04-29 | Lu Peng | Officer | S-Sale | D | Common Stock | 3,733 | 30.06 | 112.2K | 62,350 | D | ↗ |
| 2026-04-29 | Lesage Anne | Officer | S-Sale | D | Common Stock | 3,700 | 30.06 | 111.2K | 153,169 | I | ↗ |
| 2026-04-23 | Schikan Johannes Gerardus Christiaan Petrus | Director | S-Sale | D | Common Stock | 100 | 30.03 | 3.0K | 388,067 | D | ↗ |
| 2026-04-23 | Lu Peng | Officer | S-Sale | D | Common Stock | 100 | 30.03 | 3.0K | 66,083 | D | ↗ |
| 2026-04-23 | Lesage Anne | Officer | S-Sale | D | Common Stock | 100 | 30.03 | 3.0K | 156,869 | I | ↗ |
| 2026-04-22 | Schikan Johannes Gerardus Christiaan Petrus | Director | S-Sale | D | Common Stock | 7,000 | 30.05 | 210.4K | 388,167 | D | ↗ |
| 2026-04-22 | Lu Peng | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,001 | 2.59 | 18.1K | 106,307 | D | ↗ |
| 2026-04-22 | Lesage Anne | Officer | M-Exempt | A | Common Stock | 500 | 2.59 | 1.3K | 56,950 | D | ↗ |
| 2026-04-16 | Modig Berndt | Director / Officer | S-Sale | D | Common Stock | 2,292 | 28.60 | 65.6K | 139,792 | D | ↗ |
| 2026-04-16 | Lu Peng | Officer | F-InKind | D | Common Stock | 226 | 28.78 | 6.5K | 66,083 | D | ↗ |
| 2026-04-11 | Nijdam Anna | Officer | F-InKind | D | Common Stock | 548 | 26.63 | 14.6K | 48,940 | D | ↗ |
| 2026-04-11 | Bjork Elisabeth | Director | — | — | Stock Option (Right to Buy) | 14,000 | 22.31 | 312.3K | 0 | D | ↗ |
| 2026-04-09 | Modig Berndt | Director / Officer | S-Sale | D | Common Stock | 23,133 | 27.74 | 641.6K | 142,284 | D | ↗ |
| 2026-04-06 | Nijdam Anna | Officer | F-InKind | D | Common Stock | 1,167 | 28.56 | 33.3K | 49,488 | D | ↗ |
| 2026-04-01 | Nijdam Anna | Officer | F-InKind | D | Common Stock | 1,164 | 28.25 | 32.9K | 50,655 | D | ↗ |
| 2026-03-27 | Abele Stefan Andreas | Officer | — | — | Common Stock | 0 | 0.00 | — | 49,216 | D | ↗ |
| 2026-03-18 | Souverijns Wim | Officer | — | — | Common Stock | 0 | 0.00 | — | 55,111 | D | ↗ |
| 2026-03-18 | Nijdam Anna | Officer | — | — | Common Stock | 0 | 0.00 | — | 51,819 | D | ↗ |
| 2026-03-18 | Nassif David W. | Officer | — | — | Common Stock | 0 | 0.00 | — | 123,925 | D | ↗ |
| 2026-03-18 | Meeker David P | Director | — | — | Common Stock | 0 | 0.00 | — | 65,167 | D | ↗ |
| 2026-03-18 | Lu Peng | Officer | — | — | Common Stock | 0 | 0.00 | — | 66,309 | D | ↗ |
| 2026-03-18 | Lesage Anne | Officer | — | — | Stock Option (Right to Buy) | 65,000 | 18.14 | 1.18M | 0 | D | ↗ |
| 2026-03-18 | Deschoolmeester Annick | Officer | — | — | Stock Option (Right to Buy) | 45,000 | 22.31 | 1.00M | 0 | D | ↗ |
| 2026-03-18 | Bjork Elisabeth | Director | — | — | Common Stock | 0 | 0.00 | — | 15,167 | D | ↗ |
| 2026-03-18 | Abele Stefan Andreas | Officer | — | — | Stock Option (Right to Buy) | 60,000 | 16.05 | 963.0K | 0 | D | ↗ |
| 2026-03-17 | Schikan Johannes Gerardus Christiaan Petrus | Director | — | — | Stock Option (Right to Buy) | 21,000 | 8.05 | 169.1K | 0 | D | ↗ |
| 2026-03-17 | Monges Viviane | Director | — | — | Stock Option (Right to Buy) | 17,500 | 18.14 | 317.5K | 0 | D | ↗ |
| 2026-03-17 | Modig Berndt | Director / Officer | — | — | Stock Option (Right to Buy) | 210,000 | 28.00 | 5.88M | 0 | D | ↗ |
| 2026-03-17 | Glassman Robert | Director | — | — | Stock Option (Right to Buy) | 8,000 | 20.00 | 160.0K | 0 | D | ↗ |
| 2026-03-12 | Schikan Johannes Gerardus Christiaan Petrus | Director | — | — | Stock Option (Right to Buy) | 15,000 | 16.05 | 240.8K | 0 | D | ↗ |
| 2026-03-12 | Monges Viviane | Director | — | — | Stock Option (Right to Buy) | 15,000 | 16.05 | 240.8K | 0 | D | ↗ |
| 2026-03-12 | Meeker David P | Director | — | — | Stock Option (Right to Buy) | 15,000 | 16.05 | 240.8K | 0 | D | ↗ |
| 2026-03-12 | Glassman Robert | Director | — | — | Stock Option (Right to Buy) | 15,000 | 16.05 | 240.8K | 0 | D | ↗ |
| 2026-03-12 | Bjork Elisabeth | Director | — | — | Stock Option (Right to Buy) | 15,000 | 16.05 | 240.8K | 0 | D | ↗ |
| 2025-04-11 | Schikan Johannes Gerardus Christiaan Petrus | Director | — | — | Stock Option (Right to Buy) | 14,000 | 22.31 | 312.3K | 0 | D | ↗ |
| 2025-04-11 | Monges Viviane | Director | — | — | Stock Option (Right to Buy) | 14,000 | 22.31 | 312.3K | 0 | D | ↗ |
| 2025-04-11 | Meeker David P | Director | — | — | Stock Option (Right to Buy) | 14,000 | 22.31 | 312.3K | 0 | D | ↗ |
| 2025-04-11 | Glassman Robert | Director | — | — | Stock Option (Right to Buy) | 14,000 | 22.31 | 312.3K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
65.41M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | 818.0K | male |
| Anne Lesage | Chief Early Development Officer | — | — |
| Annick Deschoolmeester | Chief Human Resources Officer | — | female |
| David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | — | male |
| Maryann Cimino | Director of Corporate Relations | — | — |
| Peng Lu | Chief Medical Officer | — | — |
| Stefan Abele | Chief Technology Operations Officer | — | — |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | — | female |
| Wim Souverijns | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHVS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
